Trial Number

790-17

Age range

21 Years and older

Gender

Male

Enrolling Patients

Yes

Full Protocol Title: "Prospective Evaluation of TrueBeam / Edge Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy versus Radiosurgery Boost"

The primary safety purpose of this study is to estimate the rates of immediate and long-term high grade (grade 3-5) gastrointestinal and genitourinary side effects during the five years after TrueBeam stereotactic body radiotherapy in low-risk and intermediate-risk prostate cancer patients. The primary efficacy purpose is to compare 5 year biochemical disease free survival rates with TrueBeam to 5 year biochemical diseases free survival rates with dose-escalated external beam radiation therapy.

Principal Investigator

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.